Senate To Consider User Fee Bill Soon, As Hopes For BCRA Passage With Device Tax Repeal Fade
Executive Summary
Sen. Lamar Alexander, R-Tenn., has placed the user fee FDA Reauthorization Act on the Senate legislative calendar, and is just waiting on a nod from the chamber leadership to bring it up for consideration on the floor. On July 18, after successfully passing an Agriculture/FDA funding bill for 2018 onto the full committee, Ag/FDA Subcommittee Chair John Hoeven, R-N.D., characterized FDARA as non-controversial and ripe for passage. Meanwhile, industries' hopes for device tax repeal as part of legislation repealing the Affordable Care Act are fading away.
You may also be interested in...
MDUFA IV (And More) Is Law: Trump Signs A Health-Care Bill
President Trump's eleventh-hour signature on the FDA Reauthorization Act puts into play about $1bn in device user-fee collections from industry through FY 2022, new US FDA performance goals and a range of device process enhancements and reforms supported by industry.
Health Reform Roundtable Members Hold Conflicting Views On Device Tax Repeal For ACA Reform
A group of high-level health policy analysts – including former Medicare and Medicaid officials and experts at policy groups including Families USA and the American Enterprise Institute – have crafted a bipartisan recommendation for Affordable Care Act reform, but are divided on if the 2.3% device excise tax created by ACA should be repealed.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.